Der Urologe

, Volume 49, Issue 2, pp 211–215 | Cite as

Strahlentherapie des Prostatakarzinoms in der neuen S3-Leitlinie

Teil 1: Lokal begrenztes und lokal fortgeschrittenes Prostatakarzinom
  • D. Böhmer
  • F. Wenz
  • T. Martin
  • F. Sedlmayr
  • W. Hinkelbein
  • T. Wiegel
Leitthema

Zusammenfassung

Die Strahlentherapie ist eine Therapieoption zur kurativen Behandlung des lokal begrenzten und des lokal fortgeschrittenen Prostatakarzinoms. Abhängig vom Tumorstadium und der Konstellation der Risikofaktoren (PSA-Wert, Tastbefund und Gleason-Score) werden unterschiedliche Formen der Strahlentherapie angewandt. Bei Patienten mit niedrigen Risikofaktoren und in frühen klinischen Stadien wird neben der alleinigen perkutanen Strahlentherapie auch die alleinige Brachytherapie mit radioaktiven Seeds eingesetzt. Mit zunehmendem Rezidivrisiko ist eine Intensivierung der Therapie angezeigt. Diese kann durch zusätzlichen Einsatz einer medikamentösen hormonablativen Therapie und/oder eine Intensivierung der Strahlentherapie (Dosiseskalation) erfolgen. Auch Kombinationsbehandlungen von Brachytherapie und perkutaner Strahlentherapie werden hier eingesetzt. Bei Einsatz einer hormonablativen Therapie sollte diese, abhängig vom Rezidivrisiko, über einen Zeitraum von 3–36 Monaten als neoadjuvante und/oder adjuvante Behandlung appliziert werden.

Schlüsselwörter

S3-Leitlinie Prostatakarzinom Strahlentherapie Hormontherapie 

Radiation therapy for prostate cancer in the new S3 guideline

Part 1: localized and locally advanced prostate cancer

Abstract

Radiation therapy is a treatment option for curative management of localized and locally advanced prostate cancer. Depending on tumor stage and constellation of risk factors (PSA level, findings on digital rectal examination, and Gleason score), various forms of radiotherapy are applied. In addition to the sole use of external beam radiotherapy, brachytherapy with radioactive seeds is also employed as stand-alone treatment in patients with low risk factors and in early clinical stages. Increasing risk of recurrence requires more intensive therapies which can be accomplished by adding hormone deprivation therapy and/or intensifying radiation therapy (dose escalation). Combined approaches using brachytherapy and percutaneous radiotherapy are also initiated in these cases. If hormone ablation therapy is administered, this should occur over a course of 3–36 months as neoadjuvant, concommitant and/or adjuvant treatment, depending on the risk of recurrence.

Keywords

S3 guideline Prostate cancer Radiation therapy Hormone therapy 

Notes

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Abuzallouf S, Dayes I, Lukka H (2004) Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol 171(6):2122–2127CrossRefPubMedGoogle Scholar
  2. 2.
    Al-Mamgani A, Heemsbergen WD, Peeters ST, Lebesque JV (2009) Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 73(3):685–691PubMedGoogle Scholar
  3. 3.
    Bohrer M, Schröder P, Welzel G et al (2008) Reduced rectal toxicity with ultrasound-based image guided radiotherapy using BAT (B-mode acquisition and targeting system) for prostate cancer. Strahlenther Onkol 184:674–678CrossRefPubMedGoogle Scholar
  4. 4.
    Bolla M, Collette L, Blank L et al (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360(9327):103–106CrossRefPubMedGoogle Scholar
  5. 5.
    Bolla M, Reijke TM de, Van Tienhoven G et al (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360(24):2516–2527CrossRefPubMedGoogle Scholar
  6. 6.
    D’Amico A, Altschuler M, Whittington R et al (1993) The use of clinical parameters in an interactive statistical package to predict pathological features associated with local failure after radical prostatectomy for prostate cancer. Clin Perform Qual Health Care 1(4):219–222Google Scholar
  7. 7.
    D’Amico AV, Manola J, Loffredo M et al (2004) 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292(7):821–827CrossRefGoogle Scholar
  8. 8.
    Dearnaley DP, Khoo VS, Norman AR et al (1999) Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 353(9149):267–272CrossRefPubMedGoogle Scholar
  9. 9.
    Dearnaley DP, Sydes MR, Graham JD et al (2007) RT01 collaborators. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8(6):475–487CrossRefPubMedGoogle Scholar
  10. 10.
    Denham JW, Steigler A, Lamb DS et al (2005) Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6(11):841–850CrossRefPubMedGoogle Scholar
  11. 11.
    Engelbrecht MR, Jager GJ, Laheij RJ et al (2002) Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol 12(9):2294–2302PubMedGoogle Scholar
  12. 12.
    Granfors T, Modig H, Damber JE, Tomic R (2006) Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone. J Urol 176(2):544–547CrossRefPubMedGoogle Scholar
  13. 13.
    Hanks GE, Pajak TF, Porter A et al (2004) Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92–02. J Clin Oncol 21(21):3972–3978. Erratum in: J Clin Oncol 22(2):386Google Scholar
  14. 14.
    Heidenreich A, Aus G, Abbou CC et al (2007) European Association of Urology. EAU guidelines on prostate cancer. EAU, ArnhemGoogle Scholar
  15. 15.
    Heemsbergen WD, Peeters ST, Koper PC et al (2006) Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. Int J Radiat Oncol Biol Phys 66(1):3–10PubMedGoogle Scholar
  16. 16.
    Köhler FM, Boda-Heggemann J, Küpper B et al (2009) Phantom measurements to quantify the accuracy of a commercially available Cone Beam CT gray value matching algorithm using multiple fiducials. Strahlenther Onkol 185:49–55CrossRefPubMedGoogle Scholar
  17. 17.
    Kuban DA, Tucker SL, Dong L et al (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70(1):67–74PubMedGoogle Scholar
  18. 18.
    Kumar S, Shelley M, Harrison C et al (2006) Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 4:CD006019PubMedGoogle Scholar
  19. 19.
    Kupelian PA, Willoughby TR, Reddy CA et al (2007) Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 68(5):1424–1430PubMedGoogle Scholar
  20. 20.
    Lawton CA, DeSilvio M, Roach M 3rd et al (2007) An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94–13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69(3):646–655PubMedGoogle Scholar
  21. 21.
    Lohr F, Fuss M, Tiefenbacher U et al (2004) Optimierter Einsatz der Strahlentherapie durch IMRT und Präzisionslokalisationsverfahren bei der Behandlung des fortgeschrittenen Prostatakarzinoms. Urologe A 43:43–51CrossRefPubMedGoogle Scholar
  22. 22.
    Morris DE, Emami B, Mauch PM et al (2005) Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. Int J Radiat Oncol Biol Phys 62(1):3–19CrossRefPubMedGoogle Scholar
  23. 23.
    Peeters ST, Heemsbergen WD, Koper PC et al (2006) Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24(13):1990–1996CrossRefPubMedGoogle Scholar
  24. 24.
    Perez CA, Michalski JM, Purdy JA et al (2000) Three dimensional comformal therapy or standard irradiation in localized carcinoma of prostate: preliminary resulst of a nonrandomized comaprison. Int J Radiat Oncol Biol Phys 47(3):629–637CrossRefPubMedGoogle Scholar
  25. 25.
    Pilepich MV, Winter K, Lawton CA et al (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85–31. Int J Radiat Oncol Biol Phys 61(5):1285–1290PubMedGoogle Scholar
  26. 26.
    Pollack A, Zagars GK, Starkschall G et al (2002) Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53(5):1097–1105CrossRefPubMedGoogle Scholar
  27. 27.
    Shipley WU, Lu JD, Pilepich MV et al (2002) Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86–10. Int J Radiat Oncol Biol Phys 54(5):1302–1310PubMedGoogle Scholar
  28. 28.
    Van Poppel H, Vekemans K, Da Pozzo L et al (2006) Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001). Eur J Cancer 42(8):1062–1067CrossRefGoogle Scholar
  29. 29.
    Ward JF, Slezak JM, Blute ML et al (2005) Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 95(6):751–756CrossRefPubMedGoogle Scholar
  30. 30.
    Widmark A, Klepp O, Solberg A et al (2009) Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG- 7/SFUO-3): an open randomised phase III trial. Lancet 373(9660):301–308CrossRefPubMedGoogle Scholar
  31. 31.
    Zelefsky MJ, Yamada Y, Fuks Z et al (2008) Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 71(4):1028–1033PubMedGoogle Scholar
  32. 32.
    Zelefsky MJ, Yamada Y, Kollmeier MA et al (2008) Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer. Eur Urol 53(6):1172–1179CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2010

Authors and Affiliations

  • D. Böhmer
    • 1
  • F. Wenz
    • 2
  • T. Martin
    • 3
  • F. Sedlmayr
    • 4
  • W. Hinkelbein
    • 5
  • T. Wiegel
    • 6
  1. 1.Klinik für StrahlentherapieCharité-Universitätsmedizin Berlin, Campus-Virchow-KlinikumBerlinDeutschland
  2. 2.RadioonkologieUniversitätsklinikum MannheimMannheimDeutschland
  3. 3.Praxisgemeinschaft für Strahlentherapie und RadioonkologieBremenDeutschland
  4. 4.Klinik für Radiotherapie und Radio-OnkologieSalzburger LandesklinikenSalzburgÖsterreich
  5. 5.Klinik für Radioonkologie und StrahlentherapieCharité-Universitätsmedizin Berlin, Campus Benjamin FranklinBerlinDeutschland
  6. 6.Klinik für Strahlentherapie und RadioonkologieUniversitätsklinikum UlmUlmDeutschland

Personalised recommendations